Pharmacological modulation of cisplatin toxicity rhythms with buthionine sulfoximine in mice bearing pancreatic adenocarcinoma (PO3)

Chronobiology International

Volumn 15, Issue 4, 1998, Pages 323-335

  Li, Xiao Mei ^a   Filipski, Elisabeth ^a   Lévi, Francis ^a  

^a Lab 'Rythmes Biologiques C   (France)

Author keywords

Buthionine sulfoximine; Circadian rhythm; Cisplatin; Efficacy; Toxicity

Indexed keywords

BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA;

ANIMALIA;

EID: 0031855263     PISSN: 07420528     EISSN: None     Source Type: Journal    
DOI: 10.3109/07420529808998693     Document Type: Article

References (36)

1. Meister A. Metabolism and transport of glutathione and other γ-glutamyl compounds. In: Larson A, Orrenius S, Holmgren A, Mannervik B, eds. Functions of glutathione: biochemical, physiological, toxicological, and clinical aspects. New York: Raven Press, 1983:1-22.
2. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990; 30:603-31.
3. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53:544-49.
4. Li XM, Metzger G, Filipski E, Boughattas N, Lemaigre G, Hecquet B, Filipski J, Lévi F. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol 1997; 143:281-90.
5. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984; 44:4224-32.
6. Smith CV, Jones DP, Quenthner TM, Lash LH, Lauterburg HL. Contemporary issues in toxicology, compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol 1996; 140:1-12.
7. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 1987; 47:2056-61.
8. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, De Vries EGE. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52:6885-89.
9. Timmer-Bosscha H, Timmer A, Meijer C, de Vries EGE, de Jong B, Oosterhuis W, Mulder NH. Cis-diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res 1993; 53:5707-13.
10. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine. J Biol Chem 1987; 254:7558-60.
11. Griffith OW. L-Buthionine-SR-sulfoximine: mechanism of action, resolution of diastereomers and as a chemotherapeutic agent. In: Taniguchi N, Higashi T, Sakamoto Y, Meister A, eds. Glutathione centennial. San Diego, CA: Academic, 1989: 285-99.
12. Hamilton TC, Winker MA, Louie KG, Batist G, Brhrens BC, Tsuruo T, Grotzinger KR, Mckoy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34:2583-86.
13. Andrews PA, Schiefer MA, Murphy MP, Howell SB. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact 1988; 65:51-58.
14. Bier H. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo. Acta Oto-laryngol 1991; 111:797-806.
15. Saikawa Y, Kubota T, Kuo TH, Furukawa T, Tanino H, Watanabe M, Ishibiki K, Kitajima M. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. Jpn J Cancer Res 1993; 84: 787-93.
16. Bailey H, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Tombes MB, Wilding G, Spriggs D. Phase I trail of intravenous melphalan (L-PAM) and L-buthionine sulfoximine (BSO): an attempt at modulation of glutathione (GSH) chemoprotection [abstr]. Proc Am Soc Clin Oncol 1992; 11:114.
17. O'Dwyer PJ, Hamilton TC, Lacreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14:249-56.
18. Hrushesky W, Lévi F, Halberg F, Kennedy BJ. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res 1982; 42:945-49.
19. Lévi F, Hrushesky W, Blomquist J, Lakatua D, Haus E, Halberg F, Kennedy BJ. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 1982; 42:950-55.
20. Boughattas NA, Lévi F, Hecquet B, Lemaigre G, Roulon A, Fournier C, Reinberg A. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol 1988; 96:233-47.
21. Boughattas NA, Lévi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, Mathé G, Reinberg A. Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res 1989; 49:3362-68.
22. Boughattas NA, Lévi F, Fournier C, Hecquet B, Lemaigre G, Roulon A, Mathé G, Reinberg A. Stable circadian mechanisms of toxicity of two platinum analogs (cis-platin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Therap 1990; 255:672-79.
23. Sothern R, Lévi F, Haus E, Halberg F, Hrushesky WJM. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Nat Cancer Inst 1989; 81:135-45.
24. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, /NSC 628503), a taxol analogue. Cancer Res 1991; 51:4845-52.
25. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
26. Nelson W, Tong Y, Lee JK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6:305-23.
27. Kramer RA, Greene K, Ahmad S, Vistica DT. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res 1987; 47:1593-97.
28. Prezioso JA, FitzGerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992; 99:289-93.
29. Port JL, Hochwald SN, Wang HY, Burt ME. Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin. Ann Thorac Surg 1995; 60:239-44.
30. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717-26.
31. Hrushesky WJM. Circadian timing of cancer chemotherapy. Science 1985; 228: 73-75.
32. Lévi F, Benvavides J, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathé G. Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl adriamycin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol 1990; 8:705-14.
33. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G. Phase I trial of five-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Nat Cancer Inst 1990; 82:1046-50.
34. Lévi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997; 350:681-86.
35. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés-Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Lévi F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:2950-58.
36. Lévi F. Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B, eds. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Berlin: Springer-Verlag, 1997; 125:299-331.